Suven Life Sciences Limited — Others, 14-05-2025: Shareholders meeting

Suven Life Sciences has announced a board meeting to approve increasing its authorized share capital from ₹30 Cr to ₹50 Cr by adding 20 crore equity shares of ₹1 each. It plans to raise up to ₹857.64 Cr through up to 6.4 crore convertible warrants at ₹134 each via preferential issuance to a promoter group entity and select non-promoter investors. Funds will support clinical development, R&D, a new R&D center, and general corporate purposes. Additionally, Smt. Sudharani Jasti has been re-appointed as Whole-time Director for five years, continuing without remuneration.